More News and Clinical Research about Emerging Approaches in Schizophrenia

Divergent Perspectives Threaten Schizophrenia Treatment
news

November 5, 2024

The main challenges in treating schizophrenia arise from differing perceptions of antipsychotic side effects between patients and physicians.
Exploring the Link Between Schizophrenia and Alzheimer’s 
news

November 1, 2024

Research reveals shared cholinergic pathway dysfunction in schizophrenia and Alzheimer’s, leading to a new FDA-approved treatment.
JCP
Prevalence and Determinants of Everyday Disability in Schizophrenia
Insights

October 31, 2024

In this video, Philip D. Harvey, PhD discusses the multifaceted nature of disability in schizophrenia, highlighting the impact of cognitive impairments, functional capacity, and negative symptoms on everyday outcomes…
JCP
The Role of Digital Phenotyping in Negative Symptoms Treatment Studies
Insights

October 31, 2024

In this video, Philip D. Harvey, PhD explores the use of digital phenotyping to track negative symptoms in schizophrenia. Through ecological momentary assessments (EMA) using GPS and actigraphy, the…
JCP
Anticholinergic Burden in Schizophrenia
Insights

October 31, 2024

In this video, Philip D. Harvey, PhD discusses anticholinergic burden in schizophrenia, highlighting its cognitive impact, particularly memory impairments linked to M1 receptor blockade. He underscores the heightened dementia…
Understanding Neurotransmitters in Schizophrenia Beyond Dopamine
news

October 30, 2024

Research has revealed that multiple neurotransmitters contribute to schizophrenia, suggesting the potential for non-dopaminergic therapies.
Cholinergic Neurotransmission’s Role in Schizophrenia Symptoms
news

October 28, 2024

Cholinergic neurotransmission, an overlooked target in schizophrenia, influences brain functions, offering an alternative to antipsychotics.
Managing Weight, Metabolic Syndrome, and Diabetes in Schizophrenia Patients
news

October 17, 2024

Managing weight gain, metabolic syndrome, and diabetes in schizophrenia patients demands attention to side effects and lifestyle factors.
The History of Dopaminergic Blockade in Schizophrenia
news

October 4, 2024

Schizophrenia remains a debilitating condition that’s prompted the development of both dopamine-based and emerging non-dopaminergic therapies.
Beyond Dopamine: Evaluating the Pipeline for Schizophrenia
news

October 4, 2024

New schizophrenia drugs targeting non-dopaminergic pathways show promise in overcoming the limitations of existing therapies.
Xanomeline-Trospium and Iclepertin Show Promise in Managing Cognitive Impairment in Schizophrenia
news

October 4, 2024

Schizophrenia can cause cognitive deficits, and though no effective treatments exist, trial drugs like KarXT and Iclepertin show promise.
Schizophrenia’s Acute Psychosis Crisis Calls for Novel Treatments
news

October 4, 2024

Side effects limit most schizophrenia treatments, but emerging drugs targeting alternative pathways show promise.

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe